Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder
2007

Comparing Two Methylphenidate Treatments for Adult ADHD

Sample size: 285 publication Evidence: high

Author Information

Author(s): Biederman Joseph, Mick Eric O, Surman Craig, Doyle Robert, Hammerness Paul, Michel Evan, Martin Jessica, Spencer Thomas J

Primary Institution: Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD at the Massachusetts General Hospital, Boston, MA

Hypothesis

Once daily OROS-MPH would show similar efficacy and tolerability to that of IR-MPH administered three times a day.

Conclusion

Once daily OROS-MPH has similar efficacy and tolerability to that of IR-MPH administered three times daily.

Supporting Evidence

  • Both OROS-MPH and IR-MPH showed statistically significant improvement compared to placebo.
  • The response rate for both medications was significantly higher than placebo.
  • Adverse effects were more common in both active treatment groups compared to placebo.

Takeaway

This study looked at two types of ADHD medication for adults and found that taking one pill a day works just as well as taking three pills a day.

Methodology

Two six-week, randomized, placebo-controlled trials were conducted comparing OROS-MPH and IR-MPH in adults with ADHD.

Potential Biases

Self-reports may not fully capture ADHD symptoms, and adverse effects were assessed through spontaneous reports.

Limitations

The study had stricter ADHD criteria than DSM-IV and relied on self-reports for diagnosis and symptom assessment.

Participant Demographics

Outpatient adults aged 19 to 60 with DSM-IV ADHD.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-244X-7-49

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication